When the Federal Trade Commission allowed pharmaceutical behemoth Teva to acquire Allergan’s generic business, conditioned on relinquishing 79 of its generic drugs — the largest drug divestiture in one of the commission’s cases — the agency had a backstop to make sure the deal went off without a hitch.
This content can only be accessed by FTC:WATCH subscribers.
FTC:WATCH is published 22 times a year - twice a month except in August when Northern Hemisphere governments leave town.FTC:WATCH is delivered in the following formats:
- online at ftcwatch.com via IP address recognition for enterprise wide distribution
- online at ftcwatch.com via secure username and password
- PDF version delivered by email
If you are an FTC:WATCH subscriber, please login to access this content: